A study in women with advanced breast cancer treated with standard therapy with or without MEDI-573
- Registry ID
- EUCTR2011-000198-29
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE2
- Sponsor
- MedImmune, LLC
- Start date
- 2011-10-25
- Completion date
- 2019-06-28
- Last update
- 2026-08-16
Conditions
- Advanced Metastatic Breast Cancer (MBC)
Summary
The primary objective of the dose-evaluation phase of this study (Phase 1b) is to evaluate the safety and tolerability of two doses of MEDI-573 in combination with an AI in patients with HR+, HER2-negative MBC The primary objective of the randomization phase (Phase 2) of this study is to evaluate the PFS of subjects treated with MEDI-573 and AI versus treatment with AI alone.
Locations
- , , Belgium
- , , UK
- , , Germany
- , , Hungary
- , , Spain
View on source registry